From the American Academy of Ophthalmology
News from the FSO
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
This analysis of data from the Fuchs Endothelial Corneal Dystrophy Genetics Multi-Center Study shows that index cases and affected family members with severe disease (grade 4-6) had a higher prevalence of glaucoma and/or ocular hypertension relative to control subjects or unaffected family members. The authors suggest considering periodic glaucoma assessments when monitoring these patients, particularly those with moderate to advanced disease. Archives of Ophthalmology, November 2012
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
First-year results of two phase 3 studies comparing intravitreal aflibercept, monthly or every two months, with monthly ranibizumab show that aflibercept can potentially decrease the treatment and compliance burden of anti-VEGF treatment. Results show aflibercept dosed monthly or every two months after three initial monthly doses resulted in similar visual and anatomic outcomes as ranibizumab dosed monthly, and with a similar safety and tolerability profile. Ophthalmology, December 2012
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology